Search results
Results from the WOW.Com Content Network
When given for the evaluation or treatment of a supraventricular tachycardia (SVT), the initial dose is 6 mg to 12 mg, depending on standing orders or provider preference, [10] given as a rapid parenteral infusion.
If narrow QRS/ SVT, perform vagal maneuvers and give adenosine. If wide QRS/ VT with regular rhythm and monomorphic QRS, the provider can give adenosine and should consult pediatric cardiology for recommendations. adenosine: first dose 0.1 mg/kg with max 6 mg, second dose 0.2 mg/kg with max 12 mg [2]
If adenosine is not effective a calcium channel blocker or beta blocker may be used. [4] Otherwise synchronized cardioversion is the treatment. [4] Future episodes can be prevented by catheter ablation. [3] About 2.3 per 1000 people have paroxysmal supraventricular tachycardia. [5] Problems typically begin in those 12 to 45 years old.
Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a class of drugs that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia. Many attempts have been made to classify antiarrhythmic agents.
Supraventricular tachycardia (SVT) is an umbrella term for fast heart rhythms arising from the upper part of the heart. [2] This is in contrast to the other group of fast heart rhythms – ventricular tachycardia , which start within the lower chambers of the heart . [ 2 ]
It is also used in the emergent treatment of wide complex tachycardias, including ventricular tachycardia, when a pulse is present. Pulseless ventricular tachycardia and ventricular fibrillation are treated with unsynchronized shocks referred to as defibrillation .
AV nodal reentrant tachycardia is the most common regular supraventricular tachycardia. It is more common in women than men (approximately 75% of cases occur in females). The main symptom is palpitations. Treatment may be with specific physical maneuvers, medications, or, rarely, synchronized cardioversion.
Conditioning treatment before haematopoietic stem cell transplantation (high dose, IV), chronic myeloid leukaemia, myelofibrosis, polycythaemia vera and essential thrombocytosis Myelosuppression, seizures (high dose), tachycardia (high dose), hepatic sinusoidal obstruction syndrome (high dose), Addison-like syndrome (rare), pulmonary fibrosis ...